Published

May 11, 2025

Pomalidomide [POM1]

Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib

  1. This application for pomalidomide has been made by and the first cycle of systemic anti-cancer therapy with pomalidomide will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti- cancer therapy
  2. The patient has multiple myeloma
  3. The patient’s performance status (PS) is 0-2
  4. The patient has previously received 3 lines of treatment with adequate trials of at least all of the following options of therapy: a routinely commissioned or CDF-funded proteasome inhibitor (bortezomib/carfilzomib/ixazomib), lenalidomide and alkylating agents
  5. The patient has refractory disease to the previous line of treatment
  6. Pomalidomide will be used as outlined in the Summary of Product Characteristics (SPC)

NHS funded From: 11 April 2017

Form version:

CDF Managed Access: NA

NICE Technology Appraisal: TA427 (11 January 2017)

Current Form Version

Note

The data on this page was produced using version 1.361 of the CDF list, downloaded from an archive of NHS England’s website on 08 May 2025 at 22:10.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.